Navigation Links
Cleveland Clinic identifies mechanism in Alzheimer's-related memory loss
Date:1/19/2014

Sunday, Jan. 19, 2014, Cleveland: Cleveland Clinic researchers have identified a protein in the brain that plays a critical role in the memory loss seen in Alzheimer's patients, according to a study to be published in the journal Nature Neuroscience and posted online today.

The protein Neuroligin-1 (NLGN1) is known to be involved in memory formation; this is the first time it's been linked to amyloid-associated memory loss.

In Alzheimer's disease, amyloid beta proteins accumulate in the brains of Alzheimer's patients and induce inflammation. This inflammation leads to certain gene modifications that interrupt the functioning of synapses in the brain, leading to memory loss.

Using animal models, Cleveland Clinic researchers have discovered that during this neuroinflammatory process, the epigenetic modification of NLGN1 disrupts the synaptic network in the brain, which is responsible for developing and maintaining memories. Destroying this network can lead to the type of memory loss seen in Alzheimer's patients.

"Alzheimer's is a challenging disease that researchers have been approaching from all angles," said Mohamed Naguib, M.D., the Cleveland Clinic physician who lead the study. "This discovery could provide us with a new approach for preventing and treating Alzheimer's disease."

Previous studies from this group of researchers have also identified a novel compound called MDA7, which can potentially stop the neuroinflammatory process that leads to the modification of NLGN1. Treatment with the compound restored cognition, memory and synaptic plasticity a key neurological foundation of learning and memory in an animal model. Significant preliminary work for the first-in-man study has been completed for MDA7 including in-vitro studies and preliminary clinical toxicology and pharmacokinetic work. The Cleveland Clinic plans to initiate Phase I human studies on the safety of this class of compounds in the near future.

Alzheimer's disease is an irreversible, fatal brain disease that slowly destroys memory and thinking skills. About 5 million people in the United States have Alzheimer's disease. With the aging of the population, and without successful treatment, there will be 16 million Americans and 106 million people worldwide with Alzheimer's by 2050, according to the 2011 Alzheimer's Disease Facts and Figures report from the Alzheimer's Association.


'/>"/>

Contact: Andrea Pacetti
PACETTA@ccf.org
216-316-3040
Cleveland Clinic
Source:Eurekalert

Related biology news :

1. 2 Cleveland Clinic researchers honored for contribution to science
2. Cleveland Clinics 2013 Obesity Summit explores causes, prevention and treatment of obesity
3. Cleveland Clinic research shows gut bacteria byproduct predicts heart attack and stroke
4. Cleveland Clinic researchers discover new link between heart disease and red meat
5. Cleveland Clinic research shows anemia drug does not improve health of anemic heart failure patients
6. Cleveland Clinic develops clinical screening program for no.1 genetic cause of colon cancer
7. Cleveland Clinic researchers receive $5 million grant to discover novel pathways to heart disease
8. MedNet Solutions Announces Latest Release Of Its Innovative iMedNet EDC eClinical Solution
9. Most clinical studies on vitamins flawed by poor methodology
10. Deep sequencing of breast cancer tumors to predict clinical outcomes after single dose of therapy
11. Online tool aids clinicians efforts to treat injured workers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/30/2017)... --  Invitae Corporation (NYSE: NVTA ), ... announced that it will report its fourth quarter and ... Monday, February 13, 2017, and Invitae,s management team will ... Eastern / 1:45 p.m. Pacific. During ... results, guidance, and recent developments and will spend the ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
(Date:1/19/2017)... , January 19, 2017 According to a new ... and Forecast, 2014 - 2022," the global biometric sensor market is expected to ... to 2022. In 2015, Asia-Pacific dominated the global market ... private sectors. Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... SAN DIEGO , Feb. 23, 2017 /PRNewswire/ ... protein research tools, announced the acquisition of GenWay ... with a comprehensive service and product offering for ... "This acquisition will facilitate growth and enhance capabilities ... proteins, antibodies, and ELISA assays will nicely complement ...
(Date:2/22/2017)... 2017  Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics ... biopharmaceutical products for companion animals, will host a live conference ... to discuss financial results from the fourth quarter and full ... and investors may access the audio webcast or ... ...
(Date:2/22/2017)... , Feb. 22, 2017  PrimeVax Immuno-Oncology, Inc. ... be presenting at the Annual Biocom Global Life Science ... 2, at 11:15 AM, at the Torrey Pines Lodge, ... to the organizers at Biocom who have chosen our ... symposium of biotechnology companies, investors, and clinical researchers," said ...
(Date:2/22/2017)... ON (PRWEB) , ... February 22, 2017 , ... ... on discovery and development of precision treatments for neurodegenerative diseases, today announced it ... validate the ProMIS approach.” This is one of a series of commentaries from ...
Breaking Biology Technology: